Yanglin Wu

Yanglin Wu

Auto-generated profile, based on publicly available information

Yanglin Wu

Tongji University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Advanced Science
Verified
Journal Article
Open access
ALAng Liu
Ang Liu
MZMin Zhang
Min Zhang
YWYanglin Wu
Yanglin Wu
CZChenhui Zhang
Chenhui Zhang
QZQin Zhang
Qin Zhang
JLJun Lin
Jun Lin
Rheumatoid arthritis (RA) is an essential cause of labor loss and disability for people worldwide. Acanthopanax senticosus polysaccharide (ASPS) is one of the most important active components from A. senticosus, which exhibits various pharmacological activities such as antioxidation and immunomodulation. However, no studies have reported the application of ASPS in treating RA. This study aims to investigate the therapeutic effect of ASPS on RA and reveal its underlying mechanism. The potential therapeutic effect of ASPS against RA is initially verified in this study using the collagen‐induced arthritis model. Moreover, the protective benefits of ASPS are transmitted through the fecal microbiota and blocked by simultaneous antibiotic cocktail treatment, indicating that gut microbiota may be correlated with ASPS. The 16S rRNA sequencing using feces samples and untargeted UPLC‐MS metabolomics using serum samples further reveal that ASPS reprograms the arthritic progression triggered dysbiosis, enhances the expression of γ‐glutamylcysteine (GGC) synthetase, and enriches the serum concentration of GGC. Furthermore, metabolites GGC is found to be able to effectively interrupt NLRP3 inflammasome activation via inhibiting ASC nucleation and therefore attenuate inflammatory arthritis. Taken together, this work highlights ASPS's therapeutic potential against RA, which mainly exhibits its effects via modulating gut microbiota and regulating GGC production.

8 March 2022 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
YYYa’nAn Yan
Ya’nAn Yan
CGCheng Gao
Cheng Gao
GCGuang Chen
Guang Chen
XCXueshi Chen
Xueshi Chen
YWYanglin Wu
Yanglin Wu
LTLuyang Tao
Luyang Tao
As one form of stroke, intracerebral hemorrhage (ICH) is a fatal cerebrovascular disease, which has high morbidity and mortality and lacks effective medical treatment. Increased infiltration of inflammatory cytokines coupled with pyroptotic cell death is involved in the pathophysiological process of ICH. However, little is known about whether concomitant fracture patients have the same progression of inflammation and pyroptosis. Hence, we respectively established the mouse ICH model and ICH with bilateral tibial fracture model (MI) to explore the potential cross-talk between the above two injuries. We found that MI obviously reversed the expressions of pyroptosis-associated proteins, which were remarkably up-regulated at the acute phase after ICH. Similar results were observed in neuronal expressions via double immunostaining. Furthermore, brain edema was also significantly alleviated in mice who suffered MI, when compared with ICH alone. To better clarify the potential mechanisms that mediated this cross-talk, recombinant mouse interleukin-13 (IL-13) was used to investigate its effect on pyroptosis in the mouse MI model, in which a lower level of IL-13 was observed. Remarkably, IL-13 administration re-awakened cell death, which was mirrored by the re-upregulation of pyroptosis-associated proteins and PI-positive cell counts. The results of hemorrhage volume and behavioral tests further confirmed its critical role in regulating neurological functions. Besides, the IL-13-treated MI group showed poor outcomes of fracture healing. To sum up, our research indicates that controlling the IL-13 content in the acute phase would be a promising target in influencing the outcomes of brain injury and fracture, and meanwhile, provides new evidence in repairing compound injuries in clinics.

29 June 2026 in Autophagy
Verified
Journal Article
Closed access
YTYun Teng
Yun Teng
TWTianyi Wu
Tianyi Wu
YWYanglin Wu
Yanglin Wu
JGJun Ge
Jun Ge
RCRui Chen
Rui Chen
JZJun Zou
Jun Zou
Exosomes derived from bone marrow mesenchymal stem cells (BMSCs) represent a promising cell-free strategy for intervertebral disc degeneration (IDD). Here, we obtained oxidative stress-preconditioned exosomes (O-Exos) from BMSCs exposed to low-concentration hydrogen peroxide. Compared with exosomes from untreated cells (N-Exos), O-Exos more effectively delayed nucleus pulposus (NP) cell senescence and attenuated IDD in vitro and in vivo. The superior effects of O-Exos were associated with restoration of mitophagy and improved mitochondrial homeostasis in TNF/TNF-α-treated NP cells. BMF (Bcl2 modifying factor) was identified as a functionally relevant downstream target suppressed by O-Exos, and Bmf deficiency promoted mitophagy and alleviated IDD. Further analyses showed that O-Exos relieved the inhibitory effect of BMF on BCL2L13-LC3B coupling, thereby restoring mitophagy. In addition, exosomal Mir29a-3p was required for BMF suppression and the superior activity of O-Exos. Together, these findings identify oxidative stress preconditioning as an effective strategy to enhance exosome potency against IDD.

25 May 2026 in Autophagy
Verified
Journal Article
Closed access
TFTingting Fu
Tingting Fu
YWYanglin Wu
Yanglin Wu
BWBo Wang
Bo Wang
QZQin Zhang
Qin Zhang
LGLujun Guo
Lujun Guo
JLJun Lin
Jun Lin
Rheumatoidarthritis (RA) is an autoimmune disease accompanied by joint swelling,stiffness, and pain, leading to a sharp decline in quality of life. However,the treatment of RA still faces numerous challenges. Clinical studies indicatethat specific hypoglycemic agents alleviate the symptoms of RA, while the potentialmolecular mechanism remains unknown. Herein, we initially assess the efficacyof various categories of anti-diabetic medications including biguanides, GLP1R(glucagon like peptide 1 receptor) agonists, SLC5A2/SGLT2 (solute carrierfamily 5 member 2) inhibitors, DPP4 (dipeptidyl peptidase 4) inhibitors,sulfonylureas, thiazolidinediones, and insulin analog in RA models ofcollagen-induced arthritis (CIA) and serum-transfer arthritis (STA). Resultsdemonstrate that solely thiazolidinediones (pioglitazone [PIOG]) confersuperior efficacy, whereas the other anti-diabetic agents provide minimal or notherapeutic benefits. Mechanistically, thiazolidinediones (PIOG) activatesPPARG/PPARγ (peroxisome proliferator activated receptor gamma) to promotemitophagic flux, thereby inhibiting aberrant NLRP3 inflammasome activation andreducing pro-inflammatory factors IL1B/IL1-BETA (interleukin 1 beta) and IL18 (interleukin18) release. Notably, loss of autophagy either genetically or pharmacologicallysubstantially diminishes the anti-inflammatory effects of PIOG both in vitroand in vivo. In summary, these results offer new mechanistic insight intodisease crosstalk and support the translational value of thiazolidinedionesPIOG as a candidate for precision therapy in RA or multimorbidity of RA and type2 diabetes mellitus (T2DM).

27 February 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
YWYanglin Wu
Yanglin Wu
SLShifeng Ling
Shifeng Ling
JMJiayi Mao
Jiayi Mao
HWHongyi Wang
Hongyi Wang
BWBo Wang
Bo Wang
MCMing Cai
Ming Cai
Skeletal aging is characterized by increased fragility, reduced bone mass, and deterioration of bone microstructure. Although aging‐related immune dysfunction of macrophages, namely immunosenescence, is known to contribute to this process, the underlying mechanism remains poorly understood. Here, we find that the senescence of macrophages leads to a decrease in the expression of Sirtuin3 (Sirt3), which in turn leads to increased basal and lipopolysaccharides (LPS)‐induced protein expression of NLRP3 and facilitates the assembly of NLRP3 inflammasome in macrophages that mediates aging‐related osteoporosis. Given the phagocytic property of macrophages, we develop a genetically engineered apoptotic body‐based platform for targeted delivery of Sirt3 to macrophages and verify that Sirt3‐enriched apoptotic bodies (ABs‐Sirt3) delay skeletal aging by promoting ubiquitination and degradation of NLRP3. Our work reveals that Sirt3 plays a key role in regulating aggravated inflammatory responses that accelerate skeletal aging during macrophage senescence and illustrates a novel nanotechnology‐based therapeutic approach targeting immune senescence‐induced acceleration of skeletal aging, which may provide potential therapeutic value for human patients with age‐related osteoporosis.

25 June 2026 in Autophagy
Verified
Journal Article
Closed access
BWBo Wang
Bo Wang
YWYanglin Wu
Yanglin Wu
GLGen Li
Gen Li
ZCZhenjia Che
Zhenjia Che
QSQi Sun
Qi Sun
MCMing Cai
Ming Cai
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease primarily characterized by symmetrical synovial inflammation, leading to joint swelling, pain, and progressive cartilage and bone destruction. Unfortunately, the clinical treatment of RA still faces numerous challenges. Although melatonin (MT), the circadian rhythm hormone, is known to relieve the pathological process of RA, the underlying mechanism remains poorly understood. Herein, we assess the impacts of MT on collagen or K/BxN serum-induced arthritis (two well-established models of RA) and confirm its excellent therapeutic effect. Mechanistically, MT activates MTNR1A (melatonin receptor 1A) to promote mitophagy for the elimination of reactive oxygen (ROS) and leaked mitochondrial DNA triggered by damaged mitochondria, which in turn limits NLRP3 (NLR family pyrin domain containing 3) inflammasome activation and pro-inflammatory cytokine release. Mice with deletion of the autophagy-related gene Atg5 in myeloid cells (atg5fl/fl Lyz2/LysM-cre) barely display any benefits of MT in K/BxN serum-induced arthritis. Our results indicate that mitophagy promoted by MT is essential to deactivate NLRP3 inflammasome and alleviate the development of arthritis, which provides a candidate for the treatment of RA.